Top

Gepubliceerd in:

01-08-2013 | Artikelen

De ziekte van Parkinson: van geremde motoriek tot ontremde impulsen

Auteurs: Drs. Chris Vriend, Dr. Ysbrand van der Werf, Dr. Tommy Pattij, Dr. Pieter Voorn, prof dr. Jan Booij, mw. drs. Sonja Rutten, prof dr. Henk Berendse, mw. dr Odile van den Heuvel

Gepubliceerd in: Neuropraxis | Uitgave 4/2013

Samenvatting

Impulscontrolestoornissen (ICS) zijn relatief vaak voorkomende stoornissen bij de ziekte van Parkinson (ZvP) die gekarakteriseerd kunnen worden als het onvermogen om bepaalde (vaak schadelijke of nadelige) impulsen te onderdrukken. ICS bij de ZvP kunnen ernstige sociaal-maatschappelijke gevolgen hebben voor zowel patiënt als mantelzorger. Het is daarom belangrijk om patiënten die het risico lopen ICS te ontwikkelen vroegtijdig te identificeren. Het ontwikkelen van ICS bij de ZvP lijkt afhankelijk te zijn van een interactie tussen een individuele predispositie en behandeling met dopaminerge medicatie. Hoewel er een aantal demografische en klinische risicofactoren bekend zijn, is de pathofysiologie van ICS nog niet volledig ontrafeld. Er zijn sterke aanwijzingen dat disfunctie van het limbische fronto-striatale circuit hieraan ten grondslag ligt. Uit recente studies komt naar voren dat er ook pathofysiologische overeenkomsten bestaan tussen ICS en depressie bij de ZvP en dat het neurodegeneratieve proces van de ZvP bij beide een belangrijke rol speelt. In dit review-artikel geven we een overzicht van de recente literatuur over de neurobiologie van ICS bij de ZvP en bespreken we potentiële neurobiologische risicofactoren en de daaruit voortkomende klinische implicaties.

vorige artikel Grijzestofpathologie bij multiple sclerose: histopathologische, moleculair biologische en MRI-studies

volgende artikel Signalement

Aarsland, D., Pahlhagen, S. et al. (2012). Depression in Parkinson disease − epidemiology, mechanisms and management. Nature Reviews Neurology, 8,1, 35–47.

Aarts, E., Helmich, R.C. et al. (2012). Aberrant reward processing in Parkinson’s disease is associated with dopamine cell loss. NeuroImage, 59,4, 3339–3346.CrossRef

American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders. Washington, DC.

Antonini, A. & Cilia R. (2009). Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug safety: an international journal of medical toxicology and drug experience, 32,6, 475–488.CrossRef

Ballanger, B., Klinger, H. et al. (2012). Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Movement disorders: official journal of the Movement Disorder Society, 27,1, 84–9.CrossRef

Black, D.W. (2007). Compulsive buying disorder: a review of the evidence. CNS Spectrums, 12,2, 124–132.

Bodi, N., Keri, S. et al. (2009). Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson’s patients. Brain, 132,Pt 9, 2385–2395.CrossRef

Buckholtz, J.W., Treadway, M.T. et al. (2010). Dopaminergic network differences in human impulsivity. Science, 329,5991, 532.CrossRef

Cardoso, E. F., Maia, F.M. et al. (2009). Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. Neuroimage, 47,2, 467–472.CrossRef

Cilia, R., Ko, J.H. et al. (2010). Reduced dopamine transporter density in the ventral striatum of patients with Parkinson’s disease and pathological gambling. Neurobiology of disease, 39,1, 98–104.CrossRef

Claassen, D.O., Wildenberg, W.P. van 2 et al. (2011). The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behavioral Neuroscience, 125,4, 492–500.CrossRef

Dalley, J.W. & Roiser, J.P. (2012). Dopamine, serotonin and impulsivity. Neuroscience, 215, 42–58.PubMedCrossRef

Dalley, J.W., Fryer, T.D. et al. (2007). Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science, 315,5816, 1267–1270.CrossRef

Eimeren, T. van, Ballanger, B. et al. (2009). Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson’s disease? Neuropsychopharmacology, 34,13, 2758–2766.CrossRef

Evans, A.H., Strafella, A.P. et al. (2009). Impulsive and compulsive behaviors in Parkinson’s disease. Movement disorders : official journal of the Movement Disorder Society, 24,11, 1561–1570.CrossRef

Frank, M.J., Seeberger, L.C. et al. (2004). By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science, 306,5703, 1940–1943.CrossRef

Gerfen, C.R., Miyachi, S. et al. (2002). D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. Journal of Neuroscience, 22,12, 5042–5054.

Groenewegen, H.J. & Trimble, M. (2007). The ventral striatum as an interface between the limbic and motor systems. CNS spectrums, 12,12, 887–892.PubMed

Haber, S.N. & Knutson, B. (2010). The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 35,1, 4–26.CrossRef

Haber, S.N. & McFarland, N.R. (1999). The concept of the ventral striatum in nonhuman primates. Annals of the New York Academy of Sciences, 877, 33–48.PubMedCrossRef

Hesse, S., Meyer, P.M. et al. (2009). Monoamine transporter availability in Parkinson’s disease patients with or without depression. European Journal of Nuclear Medicine and Molecular Imaging, 36,3, 428–435.CrossRef

Heuvel, O.A. van den (2013). Risk prediction and treatment monitoring are crucial for prevention and management of compulsive dopamine use in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 00,1, doi:10.1136/jnnp-2013-305378.

Heuvel , O.A. van den, Werf , Y.D. van der et al. (2011). Impulscontrolestoornissen bij de ziekte van Parkinson en de relatie tot andere stoornissen binnen het impulsieve-compulsieve spectrum. Tijdschrift voor psychiatrie, 53,4, 211–222.

Hudson, J.I., Hiripi, E. et al. (2007). The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biological Psychiatry, 61,3, 348–358.CrossRef

Johnson, P.S., Madden, G.J. et al. (2011). Effects of acute pramipexole on preference for gambling-like schedules of reinforcement in rats. Psychopharmacology (Berl), 213, 1, 11–18.CrossRef

Joutsa, J., Martikainen, K. et al. (2012). Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism & related disorders, 18,2,155–160.CrossRef

Kano, O., Ikeda, K. et al. (2011). Neurobiology of depression and anxiety in Parkinson’s disease. Parkinson’s disease, 2011, 143547.

Martinez, D., Saccone, P.A. et al. (2012). Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: commonalities and differences with other types of addiction. Biological Psychiatry, 71,3, 192–198.CrossRef

Mayberg, H.S., Starkstein, S.E. et al. (1990). Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson’s disease. Annals of neurology, 28,1, 57–64.CrossRef

Meissner, W.G., Frasier, M. et al. (2011). Priorities in Parkinson’s disease research. Nature reviews. Drug discovery, 10,5, 377–393.CrossRef

Mentis, M.J., McIntosh, A.R. et al. (2002). Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. American Journal of Psychiatry, 159,5, 746–754.CrossRef

Narendran, R., Martinez, D. et al. (2011). Imaging of dopamine D2/3 agonist binding in cocaine dependence: a [11C]NPA positron emission tomography study. Synapse, 65,12, 1344–1349.CrossRef

Neve, K.A., Seamans, J.K. et al. (2004). Dopamine receptor signaling. Journal of receptor and signal transduction research, 24,3, 165–205.

O’Sullivan, S.S., Wu, K. et al. (2011). Cue-induced striatal dopamine release in Parkinson’s disease-associated impulsive-compulsive behaviours. Brain: a journal of neurology, 134,Pt 4, 969–978.CrossRef

Pattij, T. & Vanderschuren, L.J. (2008). The neuropharmacology of impulsive behaviour. Trends in pharmacological sciences, 29,4, 192–199.CrossRef

Potenza, M.N., Steinberg, M.A. et al. (2003). Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Archives of General Psychiatry, 60,8, 828–836.CrossRef

Prieto, G.A., Perez-Burgos, A. et al. (2009). Dopamine D(2)-class receptor supersensitivity as reflected in Ca2+ current modulation in neostriatal neurons. Neuroscience, 164,2, 345–350.CrossRef

Prieto, G.A., Perez-Burgos, A. et al. (2011). Upregulation of D2-class signaling in dopamine-denervated striatum is in part mediated by D3 receptors acting on Ca V 2.1 channels via PIP2 depletion. Journal of neurophysiology, 105,5, 2260–2274.CrossRef

Ray, N.J., Miyasaki, J.M. et al. (2012). Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson’s patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiology of disease, 48,3, 519–525.CrossRef

Remy, P., Doder, M. et al. (2005). Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain : a journal of neurology, 128,Pt 6, 1314–1322.CrossRef

Rokosik, S.L. & Napier, T.C. (2012). Pramipexole-induced increased probabilistic discounting: comparison between a rodent model of Parkinson’s disease and controls. Neuropsychopharmacology, 37,6, 1397–1408.CrossRef

Scherfler, C., Schwarz, J. et al. (2007). Role of DAT-SPECT in the diagnostic work up of parkinsonism. Movement Disorders, 22,9, 1229–1238.CrossRef

Sokoloff, P., Giros, B. et al. (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347,6289, 146–151.CrossRef

Steeves, T.D., Miyasaki, J. et al. (2009). Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain: a journal of neurology, 132,Pt 5, 1376–1385.CrossRef

Voon, V., Gao, J. et al. (2011). Dopamine agonists and risk: impulse control disorders in Parkinson’s disease. Brain: a journal of neurology, 134,Pt 5, 1438–1446.CrossRef

Voon, V., Mehta, A.R. et al. (2011). Impulse control disorders in Parkinson’s disease: recent advances. Current opinion in neurology, 24,4, 324–330.CrossRef

Voon, V., Pessiglione, M. et al. (2010). Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron, 65,1, 135–142.CrossRef

Vriend, C., Nordbeck, A.H. et al. (2013). Reduced dopamine transporter binding predates impulse control disorders in Parkinson’s disease (manuscript onder review). Amsterdam, Nederland, VU medisch centrum.

Vriend, C., Raijmakers, P. et al. (2013). Depressive symptoms in Parkinson’s disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. Journal of Neurology, Neurosurgery and Psychiatry (in druk).

Weintraub, D., Koester, J. et al. (2010). Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of neurology, 67,5, 589–595.PubMedCrossRef

Wolters, E., Werf, Y.D. van 2 et al. (2008). Parkinson’s diseaserelated disorders in the impulsive-compulsive spectrum. Journal of Neurology, 255,Suppl 5, 48–56.CrossRef

Wu, K., Politis, M. et al. (2009). Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgraduate medical journal, 85,1009, 590–596.CrossRef

Ye, Z., Hammer, A. et al. (2011). Pramipexole modulates the neural network of reward anticipation. Human Brain Mapping, 32,5, 800–811.CrossRef

Titel: De ziekte van Parkinson: van geremde motoriek tot ontremde impulsen
Auteurs: Drs. Chris Vriend
Dr. Ysbrand van der Werf
Dr. Tommy Pattij
Dr. Pieter Voorn
prof dr. Jan Booij
mw. drs. Sonja Rutten
prof dr. Henk Berendse
mw. dr Odile van den Heuvel
Publicatiedatum: 01-08-2013
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Neuropraxis / Uitgave 4/2013
Print ISSN: 1387-5817
Elektronisch ISSN: 1876-5785
DOI: https://doi.org/10.1007/s12474-013-0020-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 4/2013

Grijzestofpathologie bij multiple sclerose: histopathologische, moleculair biologische en MRI-studies

Woorden vooraf

Depressie: genen, mechanismen en farmacologie

Signalement